Bionxt reiterates BNT23001 dosing optimization study

Executive Summary

• Bionxt Solutions Inc. has initiated a 15-day dosing optimization study for its lead product, BNT23001, a proprietary sublingual cladribine formulation for treating multiple sclerosis (MS).
• This large-mass animal study is the final preclinical step before human bioequivalence testing, which is scheduled to begin in early 2026.
• The company is simultaneously advancing its global patent strategy, with favorable communications received from the European and Eurasian Patent Offices.

Key Details

• Study Initiation: A 15-day crossover dosing optimization study for BNT23001 has been launched.
• Study Timeline: The study is set to begin within two weeks, run for approximately three weeks, and is expected to complete in November, with results due in December.
• Study Purpose: The large-mass animal study aims to fine-tune dosing precision, optimize the formulation, and generate comparative drug absorption results between the sublingual formulation and the name-brand tablet formulation.
• Preclinical History: Small-animal trials (40 kg mass) previously confirmed bioequivalence and showed strong absorption rates, bioequivalence to standard oral treatments, and no signs of toxicity.
• Human Trials Schedule: Human comparative bioequivalence trials are planned to begin in early 2026 to validate drug absorption between the sublingual formulation and existing tablet versions.
• Product Mechanism: BNT23001 is an orally dissolvable thin-film formulation of cladribine delivered sublingually, designed for faster absorption, improved bioavailability, and greater patient comfort.
• Patent Status:
  • Nationalization strategy advancing in Canada, Australia, the European Union, Eurasia, New Zealand, and Japan.
  • Track 1 priority filing in the United States.
  • European Patent Office and Eurasian Patent Office have issued favorable communications, including intent-to-grant notices, accepting novelty, inventive step, and industrial applicability.

Notable Quotes

• "The company has already confirmed dosage bioequivalence in small-mass (40 kilograms) animal study will provide valuable insight into the appropriate sublingual drug load for humans," said Bionxt Solutions chief executive officer Hugh Rogers.
• "This large-mass animal study is expected to increase the formula precision in our human study and is designed to generate comparative drug absorption results between the company's sublingual formulation versus the name-brand tablet formulation. Optimization of drug load per dose and potential super bioavailability are key pieces of information that will guide the final clinical planning for our upcoming comparative human bioequivalence study," he added.